<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput xmlns:ns2="local" id="49683"><DrugName>TNF inhibitor (AIDS), Advanced Biotherapy</DrugName><DrugSynonyms><Name><Value>TNF inhibitor (AIDS), Advanced Biotherapy</Value></Name></DrugSynonyms><CompanyOriginator id="24671">Advanced Biotherapy Inc</CompanyOriginator><CompaniesSecondary><Company id="24671">Advanced Biotherapy Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="24671" type="Company"><TargetEntity id="4295901947" type="organizationId">Advanced Biotherapy Inc</TargetEntity></SourceEntity><SourceEntity id="4" type="ciIndication"><TargetEntity id="10000565" type="MEDDRA"></TargetEntity><TargetEntity id="D000163" type="MeSH"></TargetEntity><TargetEntity id="-956122641" type="omicsDisease"></TargetEntity><TargetEntity id="1124" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity></SourceEntity><SourceEntity id="381" type="Action"><TargetEntity id="1551" type="Mechanism">Anti-TNF-alpha</TargetEntity><TargetEntity id="663" type="Mechanism">TNF-alpha Antagonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-07179" type="ciTarget"><TargetEntity id="202005724971243" type="siTarget">Tumor necrosis factor</TargetEntity><TargetEntity id="4487" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="4">Acquired immune deficiency syndrome</Indication></IndicationsSecondary><ActionsPrimary><Action id="381">TNF alpha ligand inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="991">Antiviral</Action><Action id="1596">Immunomodulator</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-16T12:35:16.000Z</LastModificationDate><ChangeDateLast>2007-11-26T16:30:17.000Z</ChangeDateLast><AddedDate>2004-04-20T16:31:51.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="24671" linkType="Company"&gt;Advanced Biotherapy&lt;/ulink&gt; was developing a TNF alpha inhibitor for the potential treatment of AIDS patients unresponsive to highly active antiretroviral therapy (HAART). In April 2004, Advanced Biotherapy initiated a US phase I trial in AIDS patients [&lt;ulink linkID="533682" linkType="reference"&gt;533682&lt;/ulink&gt;]; however, by September 2007, the company had ceased all R&amp;amp;D activities and was seeking to outlicense its programs [&lt;ulink linkID="854108" linkType="Reference"&gt;854108&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In April 2004, Advanced Biotherapy initiated a US phase I trial in AIDS patients. The trial planned to enroll ten patients who were in virological failure and were unresponsive to HAART [&lt;ulink linkID="533682" linkType="reference"&gt;533682&lt;/ulink&gt;]. In March 2005, preliminary data showed that the inhibitor reduced viral load [&lt;ulink linkID="590306" linkType="Reference"&gt;590306&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="24671">Advanced Biotherapy Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="4">Acquired immune deficiency syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-09-30T00:00:00.000Z</StatusDate><Source id="854108" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="24671">Advanced Biotherapy Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="4">Acquired immune deficiency syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-04-19T00:00:00.000Z</StatusDate><Source id="533682" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-07179"><Name>TNF alpha ligand</Name><SwissprotNumbers><Swissprot>O35734</Swissprot><Swissprot>O77510</Swissprot><Swissprot>O77764</Swissprot><Swissprot>P01375</Swissprot><Swissprot>P04924</Swissprot><Swissprot>P06804</Swissprot><Swissprot>P13296</Swissprot><Swissprot>P16599</Swissprot><Swissprot>P19101</Swissprot><Swissprot>P23383</Swissprot><Swissprot>P23563</Swissprot><Swissprot>P29553</Swissprot><Swissprot>P33620</Swissprot><Swissprot>P36939</Swissprot><Swissprot>P48094</Swissprot><Swissprot>P51435</Swissprot><Swissprot>P51742</Swissprot><Swissprot>P51743</Swissprot><Swissprot>P59684</Swissprot><Swissprot>P59693</Swissprot><Swissprot>P59694</Swissprot><Swissprot>P59695</Swissprot><Swissprot>P79337</Swissprot><Swissprot>P79374</Swissprot><Swissprot>Q06599</Swissprot><Swissprot>Q19LH4</Swissprot><Swissprot>Q1G1A2</Swissprot><Swissprot>Q1WM27</Swissprot><Swissprot>Q2MH05</Swissprot><Swissprot>Q539C2</Swissprot><Swissprot>Q75N23</Swissprot><Swissprot>Q8HZD9</Swissprot><Swissprot>Q8JFG3</Swissprot><Swissprot>Q8MKG8</Swissprot><Swissprot>Q8WNR1</Swissprot><Swissprot>Q9BEA1</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="108686" number="WO-2007106811" title="Method and composition for treatment of renal disease with antibodies and their equivalents"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Advanced Biotherapy Inc" id="24671"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput>